June 8, 2015

Bruker Announces MALDI PharmaPulse™, a Breakthrough High-Throughput Screening (HTS) Solution for Drug Discovery

Label-free, MALDI-based HTS ‘in a heartbeat’ at 1 second assay time (~50,000 assays per day) with 100x less solvent cost, and faster assay development, represents a paradigm change in mass spectrometry-based HTS

St. Louis, Missouri - June 1st, 2015 - At the 63rd ASMS Conference on Mass Spectrometry and Allied Topics, Bruker (NASDAQ: BRKR) today announced a new high-throughput screening (HTS) solution designed to help pharmaceutical companies achieve high throughput, lower cost and higher specificity in drug discovery. The new MALDI PharmaPulse™ solution combines the speed, sensitivity and ease-of-use of Bruker's robust MALDI-TOF systems with industry-leading HTS robotics and automation software from HighRes Biosolutions, Inc. of Woburn, MA.

 

The new MALDI PharmaPulse solution is the latest addition to Bruker's portfolio of innovative products designed to assist pharmaceutical, biotech and CRO customers accelerate drug discovery and development. Based on the autoflexspeed MALDI TOF system, and incorporating an integrated automation solution from HighRes Biosolutions, this new HTS solution offers the fastest commercially available mass spectrometry-based screening solution with significantly lower cost per sample. In addition, its label-free detection of substrates accelerates assay development, reduces complexity of screening, and potentially minimizes artifacts from interferences with the labels used in traditional HTS technologies.

 

The unique capabilities of the novel MALDI PharmaPulse solution for driving higher throughput at dramatically lower costs for screening in drug discovery, include:

 

  • Less than 1 second per sample analysis time, comparable to the pulse of the human heart, and fast enough for true high throughput screening (HTS)
  • autoflex speed MALDI TOF equipped with proprietary 2 kHz smartbeam™-II laser
  • Integrated automation solution from HighRes Biosolutions seamlessly prepares and feeds MALDI plates from 96, 384 or 1536 assay plates
  • MALDI-detection removes need for SPE cartridges or LC columns, uses 100x less solvent per sample than conventional LC-MS methods
  • Does not require derivatization in comparison to fluorescence workflows
  • Development times for new assays and complexity is dramatically reduced without the need for chromatographic method development, SPE or MRM setup, or derivatization protocols
  • The extremely low sample volumes required for detection (typically ~1 mL) enables "Single Well Kinetic Readout" by sampling multiple time points per assay
  • The full automation, coupled with speed of MALDI TOF, enables the screening of over 50.000 compounds per day

 

Due to this unique feature set, the MALDI PharmaPulse enables pharmaceutical customers to accelerate their drug discovery efforts with higher throughput assays, delivering higher quality results while lowering costs.

 

Dr. Paul Speir, Senior Vice President for the Americas of the Bruker Daltonics division, stated: "The unique MALDI PharmaPulse solution was developed in close collaboration with leading HTS scientists in the pharmaceutical industry. These types of collaborative projects enable Bruker to deliver integrated solutions that truly meet the emerging needs of pharma customers looking for breakthroughs."

 

About Bruker Corporation

For more than 50 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific research instruments and high-value analytical solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels.

 

In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, and in microscopy, nano-analysis and industrial applications, as well as in cell biology, preclinical imaging, clinical research, microbiology and molecular diagnostics.

 

Media Contact:

Tony Lewtas

Bruker Daltonics Division

T: +1 978 663 3660 ext.1212

E: tony.lewtas@bruker.com

 

 

Investor Contact:

Joshua Young 

Vice President of Investor Relations, Bruker Corporation

T: +1 978 663 3660 ext.1479

E: joshua.young@bruker.com